NanoVibronix, Inc.

Equities

NAOV

US63008J6038

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.7585 ^USD	+1.13%		-5.19%	-34.04%

Apr. 08	NanoVibronix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	NanoVibronix, Inc. Enters into Letter of Intent with APOGEPHA Arzneimittel GmbH to Explore European Distribution Opportunity	CI

NanoVibronix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023

November 13, 2023 at 04:44 pm EST

NanoVibronix, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 0.458 million compared to USD 0.097 million a year ago. Net loss was USD 0.727 million compared to USD 0.955 million a year ago. Basic loss per share from continuing operations was USD 0.42 compared to USD 0.68 a year ago.
For the nine months, sales was USD 1.11 million compared to USD 0.854 million a year ago. Net loss was USD 2.9 million compared to USD 3.39 million a year ago. Basic loss per share from continuing operations was USD 1.73 compared to USD 2.42 a year ago.

Latest news about NanoVibronix, Inc.

NanoVibronix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 08	CI
NanoVibronix, Inc. Enters into Letter of Intent with APOGEPHA Arzneimittel GmbH to Explore European Distribution Opportunity	Dec. 04	CI
NanoVibronix, Inc. Signs Research Agreement for Clinical Study of UroShield with University of Michigan	Nov. 28	CI
NanoVibronix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Investors Eye Fed Moves as US Futures Trend Lower in Friday's Premarket	23-10-20	MT
NanoVibronix, Inc. Gains Approval for Inclusion of UroShield Products in NHS Prescription Services' Drug Tariff	23-09-27	CI
NanoVibronix Files Registration Statement on Behalf of Selling Shareholders	23-09-13	MT
NanoVibronix to Raise $5 Million Through Securities Placement	23-08-30	MT
Top Midday Gainers	23-08-30	MT
NanoVibronix, Inc. announced that it expects to receive $5 million in funding	23-08-29	CI
NanoVibronix Says It's Working to Understand Implications of CMS Decision Related to PainShield Device	23-08-29	MT
NanoVibronix, Inc. Applies for Inclusion of Uroshield Products in Nhs Prescription Services' Drug Tariff	23-08-28	CI
NanoVibronix Extends Distribution Agreement With Ultra Pain Products for Ultrasound Therapy Devices; Shares Rise	23-08-23	MT
NanoVibronix Extends Distribution Agreement with Its Largest Distributor for PainShield and PainShield Plus	23-08-23	CI
NanoVibronix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
NanoVibronix Announces Distribution Agreement with Mio-Guard	23-06-14	CI
NanoVibronix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
NanoVibronix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17	CI
NanoVibronix, Inc. Receives Positive Final Results of Independent Lifecycle Testing of PainShield Prompted by Centers for Medicare and Medicaid Services	23-03-28	CI
NanoVibronix Files Provisional Patent Application in US for UroShield Ultra; Shares Jump	23-03-21	MT
NanoVibronix, Inc. Files Provisional U.S. Patent Application for UroShield Ultra	23-03-21	CI
Nanovibronix, Inc. Announces Positive Results from Independent Product Trial of UroShield for Patients with A Spinal Cord Injury	23-03-14	CI
NanoVibronix Regains Nasdaq Compliance for Listing	23-03-03	MT
Sector Update: Health Care Stocks Mostly Remain Mixed Late Wednesday	23-02-08	MT
Sector Update: Health Care	23-02-08	MT

Chart NanoVibronix, Inc.

Duration

Period

More charts

Company Profile

NanoVibronix, Inc. is a medical device company. The Company develops medical devices utilizing its patented low intensity surface acoustic wave technology. Its products include UroShield and PainShield. UroShield is an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy and decrease pain and discomfort associated with urinary catheter use. UroShield Ultra is similar to UroShield, but is designed to prevent bacterial colonization and biofilm formation in urinary catheters. PainShield is a patch-based therapeutic ultrasound technology to treat pain, muscle spasm and joint contractures by delivering a localized ultrasound effect to treat pain and induce soft tissue healing in a targeted area. Its PainShield family of products includes PainShield MD, PainShield Plus and WoundShield. WoundShield is a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-01 - Planet MicroCap Showcase

More about the company

Income Statement Evolution

More financial data

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
NANOVIBRONIX, INC.	-34.04%	2.11M
ABBOTT LABORATORIES	-2.31%	187B
MEDTRONIC PLC	-3.20%	106B
BECTON, DICKINSON AND COMPANY	-5.04%	66.9B
DEXCOM, INC.	+0.20%	49.45B
CENCORA, INC.	+17.29%	48B
HOYA CORPORATION	+4.06%	40.84B
METTLER-TOLEDO INTERNATIONAL, INC.	+2.07%	26.48B
WEST PHARMACEUTICAL SERVICES, INC.	+2.36%	26.25B
TERUMO CORPORATION	+12.96%	24.62B

Other Medical Equipment, Supplies & Distribution